Three patients. Three tumor reductions. One mission that started with a mother.
Dr. Stella Vnook didn't set out to build another biotech company. She'd already spent 20 years launching drugs inside big pharma's C-suite. She had the title, the salary, the stability.
Then her mom got ovarian cancer.
And Stella watched — helplessly, furiously — as the woman who raised her was put on a 40-year-old generic chemotherapy regimen so toxic her body eventually rejected it. Platinum resistance, they call it. In layman's terms: your body becomes allergic to the only drug standing between you and the tumor.
Her mom didn't make it.
That's the story behind this week's episode of Invst Guru. And it's the reason Stella now runs Kaeda Biopharma — a private biotech company developing what could be the first real innovation in ovarian cancer treatment in a generation.
Why this drug is different
The drug is called KAD101. Here's the elevator version:
About 80% of ovarian cancer patients overexpress something called the prolactin receptor. Think of prolactin as gasoline poured on a tumor — it makes cancer cells grow faster, stronger, more aggressive. KAD101 blocks that receptor.
But here's where it gets wild. The company is named Kaeda after the mythical dragon that eats its own tail. Why? Because KAD101 doesn't just slow the tumor down. It triggers a process called autophagy — it makes cancer cells eat themselves.
Three patients have already been dosed.
All three showed tumor reductions.
Side effects? Almost nothing — a daily injection for 29 days that women actually tolerated. Compare that to current treatments that leave patients so exhausted their immune systems can't try anything else.
But this isn't just a science story
It's also a brutal honest conversation about what it takes to fund biotech in 2026.
Stella doesn't pull punches. In this episode, she breaks down:
→ Why the IPO market collapsed from 100+ biotechs in 2021 to barely a handful in 2025 — and what that means for early-stage capital
→ The 40% cut to NIH funding and how it's quietly killing the pipeline before it even starts
→ Trump's Most Favored Nation executive order and HR 7837 — and why it's spooking investors who used to write biotech checks without blinking
→ Why so many investors are now redirecting capital from pharma into AI and fintech ("maybe I'll stick to fintech," as she puts it)
→ Why she thinks the U.S. is quietly dismantling the very innovation engine it claims to want to protect
If you've been following the biotech bear market and wondering what's actually happening on the ground, this is the unfiltered founder's view.
The part that hit hardest
About halfway through the conversation, Jeff asked Stella about the so-called "ovarian cancer gap" — why women keep getting diagnosed too late, why male-dominated investor pools keep skipping women's health, and why a condition that affects millions still gets a fraction of the funding testicular cancer does.
Her answer wasn't what you'd expect.
She refused to frame it as a male-versus-female problem. Instead, she pointed somewhere harder — and more honest — than most founders are willing to go on a podcast.
You'll want to hear that part for yourself.
Why this episode matters for investors
If you're an accredited investor who's been curious about biotech but felt locked out by the jargon, this is the one to watch. Stella breaks down:
Realistic FDA timelines (spoiler: 6 years if you're lucky, 10 if you're normal)
How biotech IP actually works (Kaeda's patents run through 2049)
Why fractional teams are the modern startup model
What questions every investor should be asking before they write a check
And the one thing biotech offers that no other asset class can
Her quote on that last one is going to stick with you:
"Your money enabled a treatment that has 10-year survival versus 12 to 16 months. You can't buy that with any other investors. With biotech, it's almost personal. It's legacy-creating."
🎬 Watch the full episode
This one runs ~35 minutes. It moves fast. And it's one of the most honest conversations we've had on the show about what it actually takes to build something that matters in a market that's actively pushing against you.
Connect with Kaeda Biopharma
🔗 Website: kaedabiopharma.com
📧 Contact: [email protected]
💼 Dr. Stella Vnook: Connect on LinkedIn
Until next week —
Jeff "Fuzzy" Wenzel Host, Invst Guru invst.guru
P.S. — If this episode resonates with you, forward it to one person who needs to hear it. Maybe it's an investor who keeps overlooking women's health. Maybe it's someone whose family has been touched by ovarian cancer. Maybe it's a founder who's about to give up. Stella almost did. Twice. She's still here.
This newsletter is for informational and educational purposes only and does not constitute investment, medical, legal, or tax advice. Investments are speculative, illiquid, and involve a high risk of loss, including total loss of principal. Always conduct your own due diligence and consult a licensed advisor before making any investment decision.
